Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price raised by research analysts at JPMorgan Chase & Co. from $32.00 to $36.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 116.35% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $39.83.

Day One Biopharmaceuticals Stock Up 8.2 %

Shares of DAWN opened at $16.64 on Monday. The company has a market capitalization of $1.45 billion, a P/E ratio of -6.99 and a beta of -1.48. The firm has a 50 day moving average of $15.27 and a 200 day moving average of $13.78. Day One Biopharmaceuticals has a twelve month low of $9.67 and a twelve month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, sell-side analysts expect that Day One Biopharmaceuticals will post -2.66 EPS for the current year.

Insiders Place Their Bets

In other news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total transaction of $160,200.00. Following the transaction, the insider now owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the transaction, the insider now owns 1,224,662 shares in the company, valued at approximately $19,729,304.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $16.02, for a total transaction of $160,200.00. Following the transaction, the insider now owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,781 shares of company stock valued at $883,160. Company insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC lifted its stake in shares of Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after buying an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after buying an additional 8,522 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Day One Biopharmaceuticals by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock valued at $677,000 after buying an additional 27,598 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of Day One Biopharmaceuticals by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after buying an additional 25,414 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.